Sequence Alignment

RESULT 2
AAY50932
ID AAY50932 standard; Protein; 441 AA.
XX
AC AAY50932;
XX
DT 10-MAR-2000 (first entry)
XX
DE Human fetal brain cDNA clone vc26_1 derived protein #1.
XX
KW Human; secreted protein; treatment; nutritional activity; cytokine;
KW cell proliferation; cell differentiation; hematopoiesis regulation;
KW tissue growth; activin; inhibin; chemotactic; chemokinetic; hemostatic;
KW thrombolytic; anti-inflammatory; invasion suppressor; tumor inhibition;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN WO9955721-A1.
XX
PD 04-NOV-1999.
XX
PF 23-APR-1999; 99WO-US08504.
XX
PR 24-APR-1998; 98US-0082904.
PR 11-JUN-1998; 98US-0088994.
PR 12-JUN-1998; 98US-0089278.
PR 02-JUL-1998; 98US-0091647.
PR 24-AUG-1998; 98US-0097639.
PR 22-APR-1999; 99US-0097639.
XX
PA (ALPH-) ALPHAGENE INC.
XX
PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
XX
DR WPI; 2000-052801/04.
DR N-PSDB; AAZ43798.
XX
PT New polynucleotides encoding secreted human proteins, derived from
PT human fetal brain, adult skin, adult brain, adult heart, adult thymus
PT and adult aorta cDNA libraries.
XX
PS Claim 53a; Page 246-247; 282pp; English.
XX
CC This invention describes novel human secreted proteins which are encoded
CC by polynucleotides obtained from fetal brain, adult skin, adult brain,
CC adult heart, adult thymus and adult aorta cDNA libraries. The
CC polynucleotides and proteins are predicted to have biological activities
CC which would make them suitable for treating, preventing or ameliorating
CC medical conditions in humans and animals, although no supporting data
CC is given. Suggested activities include nutritional activity, cytokine
CC and cell proliferation/differentiation activity, immune stimulating
CC (e.g. as vaccines) or suppressing activity, hematopoiesis regulating
CC activity, tissue growth activity, activin/inhibin activity,
CC chemotactic/chemokinetic activity, hemostatic and thrombolytic activity,
CC receptor/ligand activity, anti-inflammatory activity, cadherin/tumor
CC invasion suppressor activity, and tumor inhibition activity. The
CC polynucleotides are also stated to be useful for gene therapy.
CC AAY50905-Y50947 represent the secreted proteins described in the method
CC of the invention which are encoded by the polynucleotides represented in
CC AAZ43777-Z43808.
XX
SQ Sequence 441 AA;

Query Match 100.0%; Score 2326; DB 21; Length 441;
Best Local Similarity 100.0%; Pred. No. 6.5e-241;
Matches 441; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MAIHKALVMCLGLPLFLFPGAWAQGHVPPGCSQGLNPLYYNLCDRSGAWGIVLEAVAGAG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 maihkalvmclglplflfpgawaqghvppgcsqglnplyynlcdrsgawgivleavagag 60

Qy      61 IVTTFVLTIILVASLPFVQDTKKRSLLGTQVFFLLGTLGLFCLVFACVVKPDFSTCASRR 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 ivttfvltiilvaslpfvqdtkkrsllgtqvfflgtlglfclvfacvvkpdfstcasrr 120

Qy     121 FLFGVLFAICFSCLAAHVFALNFLARKNHGPRGWVIFTVALLLTLVEVIINTEWLIITLV 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 flfgvlfaicfsclaahvfalnflarknhgprgwviftvallltlveviintewliitlv 180

Qy     181 RGSGEGGPQGNSSAGWAVASPCAIANMDFVMALIYVMLLLLGAFLGAWPALCGRYKRWRK 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 rgsgeggpqgnssagwavaspcaianmdfvmaliyvmlllgaflgawpalcgrykrwrk 240

Qy     241 HGVFVLLTTATSVAIWVVWIVMYTYGNKQHNSPTWDDPTLAIALAANAWAFVLFYVIPEV 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 hgvfvlltttatsvaiwvvwivmytygnkqhnsptwddptlaialaanawafvlfyvipev 300

Qy     301 SQVTKSSPEQSYQGDMYPTRGVGYETILKEQKGQSMFVENKAFSMDEPVAAKRPVSPYSG 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 sqvtksspeqsyqgdmyptrgvgyetilkeqkgqsmfvenkafsmdepvaakrpvspysg 360

Qy     361 YNGQLLTSVYQPTEMALMHKVPSEGAYDIILPRATANSQVMGSANSTLRAEDMYSAQSHQ 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 yngqlltsvyqptemalmhkvpsegaydiilpratansqvmgsanstlraedmysaqshq 420

Qy     421 AATPPKDGKNSQVFRNPYVWD 441
          |||||||||||||||||||||
Db     421 aatppkdgknsqvfrnpyvwd 441
```

RESULT 3
AAZ43798
ID AAZ43798 standard; cDNA; 1936 BP.
XX
AC AAZ43798;
XX
DT 10-MAR-2000 (first entry)
XX
DE Human fetal brain cDNA clone vc26_1.
XX
KW Human; secreted protein; treatment; nutritional activity; cytokine;
KW cell proliferation; cell differentiation; hematopoiesis regulation;
KW tissue growth; activin; inhibin; chemotactic; chemokinetic; hemostatic;
KW thrombolytic; anti-inflammatory; invasion suppressor; tumor inhibition;
KW gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO9955721-A1.
XX
PD 04-NOV-1999.
XX
PF 23-APR-1999; 99WO-US08504.
XX
PR 24-APR-1998; 98US-0082904.
PR 11-JUN-1998; 98US-0088994.
PR 12-JUN-1998; 98US-0089278.
PR 02-JUL-1998; 98US-0091647.
PR 24-AUG-1998; 98US-0097639.
PR 22-APR-1999; 99US-0097639.
XX
PA (ALPH-) ALPHAGENE INC.
XX
PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
XX
DR WPI; 2000-052801/04.
DR P-PSDB; AAY50932, AAY50933.
XX
PT New polynucleotides encoding secreted human proteins, derived from
PT human fetal brain, adult skin, adult brain, adult heart, adult thymus
PT and adult aorta cDNA libraries.
XX
PS Claim 52a; Page 245-246; 282pp; English.
XX
CC This invention describes novel human secreted proteins which are encoded
CC by polynucleotides obtained from fetal brain, adult skin, adult brain,
CC adult heart, adult thymus and adult aorta cDNA libraries. The
CC polynucleotides and proteins are predicted to have biological activities
CC which would make them suitable for treating, preventing or ameliorating
CC medical conditions in humans and animals, although no supporting data
CC is given. Suggested activities include nutritional activity, cytokine
CC and cell proliferation/differentiation activity, immune stimulating
CC (e.g. as vaccines) or suppressing activity, hematopoiesis regulating
CC activity, tissue growth activity, activin/inhibin activity,
CC chemotactic/chemokinetic activity, hemostatic and thrombolytic activity,
CC receptor/ligand activity, anti-inflammatory activity, cadherin/tumor
CC invasion suppressor activity, and tumor inhibition activity. The
CC polynucleotides are also stated to be useful for gene therapy.
CC AAZ43777-Z43808 represent the polynucleotides described in the invention
CC which encode the proteins represented in AAY50905-Y50947.
XX
SQ Sequence 1936 BP; 449 A; 581 C; 532 G; 374 T; 0 other;

Query Match 98.9%; Score 1798.8; DB 21; Length 1936;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 1803; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```
Qy      10 ccctcaccagccggaaagtacgagtcggctcagcctggagggacccaaccagagcctggc 69
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      15 ccctcaccagccggaaagtacgagtcggctcagcctggagggacccaaccagagcctggc 74

Qy      70 ctgggagccaggatggccatccacaaagccttggtgatgtgcctgggactgcctctcttc 129
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      75 ctgggagccaggatggccatccacaaagccttggtgatgtgcctgggactgcctctcttc 134

Qy     130 ctgttcccaggggcctgggcccagggccatgtcccacccggctgcagccaaggcctcaac 189
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     135 ctgttcccaggggcctgggcccagggccatgtcccacccggctgcagccaaggcctcaac 194

Qy     190 cccctgtactacaacctgtgtgaccgctctggggcgtggggcatcgtcctggaggccgtg 249
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     195 cccctgtactacaacctgtgtgaccgctctggggcgtggggcatcgtcctggaggccgtg 254

Qy     250 gctggggcgggcattgtcaccacgtttgtgctcaccatcatcctggtggccagcctcccc 309
```

```
Db    255 gctggggcgggcattgtcaccacgtttgtgctcaccatcatcctggtggccagcctcccc 314
Qy    310 tttgtgcaggacaccaagaaacggagcctgctggggacccaggtattcttccttctgggg 369
Db    315 tttgtgcaggacaccaagaaacggagcctgctggggacccaggtattcttccttctgggg 374
Qy    370 accctgggcctcttctgcctcgtgtttgcctgtgtggtgaagcccgacttctccacctgt 429
Db    375 accctgggcctcttctgcctcgtgtttgcctgtgtggtgaagcccgacttctccacctgt 434
Qy    430 gcctctcggcgcttcctctttggggttctgttcgccatctgcttctcttgtctggcggct 489
Db    435 gcctctcggcgcttcctctttggggttctgttcgccatctgcttctcttgtctggcggct 494
Qy    490 cacgtctttgccctcaacttcctggcccggaagaaccacgggccccggggctgggtgatc 549
Db    495 cacgtctttgccctcaacttcctggcccggaagaaccacgggccccggggctgggtgatc 554
Qy    550 ttcactgtggctctgctgctgaccctggtagaggtcatcatcaatacagagtggctgatc 609
Db    555 ttcactgtggctctgctgctgaccctggtagaggtcatcatcaatacagagtggctgatc 614
Qy    610 atcaccctggttcggggcagtggcgagggcggccctcagggcaacagcagcgcaggctgg 669
Db    615 atcaccctggttcggggcagtggcgagggcggccctcagggcaacagcagcgcaggctgg 674
Qy    670 gccgtggcctcccccctgtgccatcgccaacatggactttgtcatggcactcatctacgtc 729
Db    675 gccgtggcctcccccctgtgccatcgccaacatggactttgtcatggcactcatctacgtc 734
Qy    730 atgctgctgctgctgggtgccttcctgggggcctggcccgccctgtgtggccgctacaag 789
Db    735 atgctgctgctgctgggtgccttcctgggggcctggcccgccctgtgtggccgctacaag 794
Qy    790 cgctggcgtaagcatggggtctttgtgctcctcaccacagccacctccgttgccatatgg 849
Db    795 cgctggcgtaagcatggggtctttgtgctcctcaccacagccacctccgttgccatatgg 854
Qy    850 gtggtgtggatcgtcatgtatacttacggcaacaagcagcacaacagtcccacctgggat 909
Db    855 gtggtgtggatcgtcatgtatacttacggcaacaagcagcacaacagtcccacctgggat 914
Qy    910 gaccccacgctggccatcgccctcgccgccaatgcctgggccttcgtcctcttctacgtc 969
Db    915 gaccccacgctggccatcgccctcgccgccaatgcctgggccttcgtcctcttctacgtc 974
Qy    970 atccccgaggtctcccaggtgaccaagtccagcccagagcaaagctaccaggggacatg 1029
Db    975 atccccgaggtctcccaggtgaccaagtccagcccagagcaaagctaccaggggacatg 1034
Qy   1030 taccccacccggggcgtgggctatgagaccatcctgaaagagcagaagggtcagagcatg 1089
Db   1035 taccccacccggggcgtgggctatgagaccatcctgaaagagcagaagggtcagagcatg 1094
Qy   1090 ttcgtggagaacaaggccttttccatggatgagccggttgcagctaagaggccggtgtca 1149
Db   1095 ttcgtggagaacaaggccttttccatggatgagccggttgcagctaagaggccggtgtca 1154
Qy   1150 ccatacagcgggtacaatgggcagctgctgaccagtgtgtaccagcccactgagatggcc 1209
Db   1155 ccatacagcgggtacaatgggcagctgctgaccagtgtgtaccagcccactgagatggcc 1214
Qy   1210 ctgatgcacaaagttccgtccgaaggagcttacgacatcatcctcccacgggccaccgcc 1269
Db   1215 ctgatgcacaaagttccgtccgaaggagcttacgacatcatcctcccacgggccaccgcc 1274
Qy   1270 aacagccaggtgatgggcagtgccaactcgaccctgcgggctgaagacatgtactcggcc 1329
Db   1275 aacagccaggtgatgggcagtgccaactcgaccctgcgggctgaagacatgtactcggcc 1334
Qy   1330 cagagccaccaggcggccacaccgccgaaagacggcaagaactctcaggtctttagaaac 1389
Db   1335 cagagccaccaggcggccacaccgccgaaagacggcaagaactctcaggtctttagaaac 1394
Qy   1390 ccctacgtgtgggactgagtcagcggtggcgaggagaggcggtcggatttggggagggcc 1449
Db   1395 ccctacgtgtgggactgagtcagcggtggcgaggagaggcggtcggatttggggagggcc 1454
Qy   1450 ctgaggacctggccccgggcaagggactctccaggctcctcctcccccctggcaggcccag 1509
Db   1455 ctgaggacctggccccgggcaagggactctccaggctcctcctcccccctggcaggcccag 1514
Qy   1510 caacatgtgccccagatgtggaagggcctccctctctgccagtgtttgggtgggtgtcat 1569
Db   1515 caacatgtgccccagatgtggaagggcctccctctctgccagtgtttgggtgggtgtcat 1574
Qy   1570 gggtgtccccacccactcctcagtgtttgtggagtcgaggagccaaccccagcctcctgc 1629
Db   1575 gggtgtccccacccactcctcagtgtttgtggagtcgaggagccaaccccagcctcctgc 1634
Qy   1630 caggatcacctcggcggtcacactccagccaaatagtgttctcggggtggtggctgggca 1689
Db   1635 caggatcacctcggcggtcacactccagccaaatagtgttctcggggtggtggctgggca 1694
Qy   1690 gcgcctatgtttctctggagattcctgcaacctcaagagacttcccaggcgctcaggcct 1749
Db   1695 gcgcctatgtttctctggagattcctgcaacctcaagagacttcccaggcgctcaggcct 1754
Qy   1750 ggatcttgctcctctgtgaggaacaagggtgcctaataaaatacatttctgctttattaac 1809
Db   1755 ggatcttgctcctctgtgaggaacaagggtgcctaataaaatacatttctgctttaaaaaa 1814
Qy   1810 tcttaaaaaa 1819
Db   1815 aaaaaaaaaa 1824
```

Sequence Alignment


```
RESULT 8
US-10-097-065-146
; Sequence 146, Application US/10097065
; Publication No. US20030055236A1

; GENERAL INFORMATION:
;  APPLICANT: Moore, Paul A. et al.
;  TITLE OF INVENTION: 110 Human Secreted Proteins
;  FILE REFERENCE: PZ021P1
;  CURRENT APPLICATION NUMBER: US/10/097,065
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: PCT/US98/27059
;  PRIOR FILING DATE: 1998-12-17
;  PRIOR APPLICATION NUMBER: 60/070,923
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,007
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,057
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,006
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,369
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,367
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,368
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,169
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,053
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,064
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,054
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,008
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,365
;  PRIOR FILING DATE: 1997-12-19
;  NUMBER OF SEQ ID NOS: 672
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 146
;  LENGTH: 400
;  TYPE: PRT
;  ORGANISM: Homo sapiens
;  FEATURE:
;  NAME/KEY: SITE
;  LOCATION: (400)
;  OTHER INFORMATION: Xaa equals stop translation
US-10-097-065-146

  Query Match           87.1%;  Score 384;  DB 9;  Length 400;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches  384;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAIHKALVMCLGLPLFLFPGAWAQGHVPPGCSQGLNPLYYNLCDRSGAWGIVLEAVAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAIHKALVMCLGLPLFLFPGAWAQGHVPPGCSQGLNPLYYNLCDRSGAWGIVLEAVAGAG 60

Qy         61 IVTTFVLTIILVASLPFVQDTKKRSLLGTQVFFLLGTLGLFCLVFACVVKPDFSTCASRR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 IVTTFVLTIILVASLPFVQDTKKRSLLGTQVFFLLGTLGLFCLVFACVVKPDFSTCASRR 120

Qy        121 FLFGVLFAICFSCLAAHVFALNFLARKNHGPRGWVIFTVALLLTLVEVIINTEWLIITLV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLFGVLFAICFSCLAAHVFALNFLARKNHGPRGWVIFTVALLLTLVEVIINTEWLIITLV 180

Qy        181 RGSGEGGPQGNSSAGWAVASPCAIANMDFVMALIYVMLLLLGAFLGAWPALCGRYKRWRK 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 RGSGEGGPQGNSSAGWAVASPCAIANMDFVMALIYVMLLLLGAFLGAWPALCGRYKRWRK 240

Qy        241 HGVFVLLTTATSVAIWVVWIVMYTYGNKQHNSPTWDDPTLAIALAANAWAFVLFYVIPEV 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 HGVFVLLTTATSVAIWVVWIVMYTYGNKQHNSPTWDDPTLAIALAANAWAFVLFYVIPEV 300

Qy        301 SQVTKSSPEQSYQGDMYPTRGVGYETILKEQKGQSMFVENKAFSMDEPVAAKRPVSPYSG 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 SQVTKSSPEQSYQGDMYPTRGVGYETILKEQKGQSMFVENKAFSMDEPVAAKRPVSPYSG 360

Qy        361 YNGQLLTSVYQPTEMALMHKVPSE 384
              ||||||||||||||||||||||||
Db        361 YNGQLLTSVYQPTEMALMHKVPSE 384
```